Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 15,045,000 $ 28,918,000
Prepaid expenses and other current assets 1,381,000 593,000
Total Current Assets 16,426,000 29,511,000
Property and equipment, net 367,000 607,000
Right of Use Asset 419,000 0
Deposits and other assets 23,000 23,000
Total Assets 17,235,000 30,141,000
Current Liabilities:    
Accounts payable 2,315,000 1,034,000
Accrued expenses 1,776,000 919,000
Accrued employee benefits 935,000 1,332,000
Deferred rent 0 99,000
Lease liability 249,000 0
Total Current Liabilities 5,275,000 3,384,000
Deferred rent - Long term 0 302,000
Lease liability - Long term 473,000 0
Total Liabilities 5,748,000 3,686,000
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized;120,000 issued and outstanding 12,544,000 12,296,000
Stockholders' Equity:    
Common stock, $0.001 par value; 200,000,000 shares authorized, 16,808,758 issued and 16,806,430 outstanding and 15,484,411 issued and 15,482,083 outstanding 17,000 15,000
Additional paid-in capital 232,580,000 230,754,000
Accumulated deficit (235,537,000) (219,461,000)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 1,821,000 17,068,000
Non-controlling interest (2,878,000) (2,909,000)
Total Stockholders' (Deficit) Equity (1,057,000) 14,159,000
Total Liabilities and Stockholders' Equity 17,235,000 30,141,000
Series B Preferred Stock [Member]    
Stockholders' Equity:    
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 7,638 issued and outstanding and 9,161 issued and outstanding 4,761,000 5,760,000
Total Stockholders' (Deficit) Equity $ 4,761,000 $ 5,760,000